Of the 1298 eligible patients who began NET, 933 (71.9%) (anastrozole: n = 289; fulvestrant: n = 306; A+F: n = 338) had week 4 or week 12 Ki67 10% or less or insufficient tumor cells to ascertain week 4 or week 12 Ki67 and completed 6 cycles of NET and surgery (Figure). Here, MKI67 is linked to neoplasm.